Patents Assigned to Arrow Therapeutics Limited
-
Patent number: 8853204Abstract: A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.Type: GrantFiled: March 18, 2005Date of Patent: October 7, 2014Assignee: Arrow Therapeutics LimitedInventors: Kenneth Powell, Richard Kelsey, Malcolm Carter, Dagmar Alber, Lara Wilson, Elisa Henderson, Phil Chambers, Debra Taylor, Stan Tyms, Verity Dowdell
-
Patent number: 8119630Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; -each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R? wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; -n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; —R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR6; —X represents —CO—, —S(O)— or —S(0)2—; and —R6 represents C1-6 alkyl, hydroxy, C1-6 alkType: GrantFiled: June 2, 2009Date of Patent: February 21, 2012Assignee: Arrow Therapeutics LimitedInventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
-
Publication number: 20110059043Abstract: The invention concerns benzodiazepine derivatives of Formula I: wherein W, X, L1, L2, L3, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment or prophylaxis of hepatitis C virus infection.Type: ApplicationFiled: September 2, 2010Publication date: March 10, 2011Applicant: ARROW THERAPEUTICS LIMITEDInventors: Michael Christopher Stratton BARNES, Helena Jade DENNISON, Stephen Sean FLACK, James Andrew LUMLEY, Pui Shan PANG, Keith Charles SPENCER
-
Publication number: 20100278835Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined in the specification, and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of respiratory syncytial virus (RSV).Type: ApplicationFiled: March 9, 2010Publication date: November 4, 2010Applicants: ASTRAZENECA UK LIMITED, ARROW THERAPEUTICS LIMITEDInventors: Helen Blade, Heather Marie Jackson, Gary Peter Tomkinson, Elisa Ann Carron, James Andrew Lumley, Christopher John Pilkington, Alexander James Floyd Thomas, Justin Warne
-
Publication number: 20100215618Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6 and L are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are useful in the treatment of hepatitis C virus.Type: ApplicationFiled: February 23, 2010Publication date: August 26, 2010Applicant: Arrow Therapeutics LimitedInventors: Malcolm Clive Carter, Neil Mathews
-
Publication number: 20100158863Abstract: A quinazoline derivative of formula (I), or a pharmaceutically acceptable salt thereof: formula (I) for use in treatment of prevention of a flaviviridae infection.Type: ApplicationFiled: January 11, 2007Publication date: June 24, 2010Applicant: ARROW THERAPEUTICS LIMITEDInventors: Neil Mathews, Alexander James Floyd Thomas, Keith Charles Spencer, Nathalie Tiberghien, Christopher John Pilkington, Lyn Jennens, Surinder Chana, Ian John Fraser
-
Publication number: 20100015063Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; -each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, —CO2R?, CONR?R?, —NH—CO—R?, —S(O)R?, —S(O)2R?, —NH—S(O)2R?, —S(O)NR?R? or —S(O)2NR?R? wherein each R? and R? is the same or different and represents hydrogen or C1-6 alkyl; -n is from 0 to 3; R4 represents hydrogen or C1-6 alkyl; —R6 represents C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR6; —X represents —CO—, —S(O)— or —S(0)2—; and —R6 represents C1-6 alkyl, hydroxy, C1-6 alkType: ApplicationFiled: June 2, 2009Publication date: January 21, 2010Applicant: Arrow Therapeutics LimitedInventors: Malcolm Carter, Elisa Henderson, Richard Kelsey, Lara Wilson, Phil Chambers, Debra Taylor, Stan Tyms
-
Patent number: 7582624Abstract: Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV.Type: GrantFiled: September 22, 2003Date of Patent: September 1, 2009Assignee: Arrow Therapeutics LimitedInventors: Malcolm Carter, Philip Chambers, Verity Dowdell, Elisa Ann Henderson, Richard David Kelsey, Debra Taylor, Stanley Tyms, Lara Wilson
-
Publication number: 20080311076Abstract: Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses, wherein R1, R2, R3 and R4 are as defined in the claims.Type: ApplicationFiled: April 28, 2005Publication date: December 18, 2008Applicant: ARROW THERAPEUTICS LIMITEDInventors: Keith Charles Spencer, Helena Dennison, Neil Mathews, Michael Christopher Barnes, Surinder Singh Chana
-
Publication number: 20080114008Abstract: Compounds of formula (I) are found to be active in inhibiting replication of flaviviridac Formula (I) wherein: X represents a direct bond or a moiety -L-NR—, wherein R is hydrogen or C1-C4 alkyl, and L represents a C1-C4alkylene, C6-C10 aryl or 5- to 10-membered heteroaryl moiety; either R1 and R2, together with the N atom to which they are attached, form a 5- to 10-membered heterocyclyl group or a 5- to 10-membered heteroaryl group, or R1 represents hydrogen, C6-C10 aryl, C1-C4 alkyl or C1-C4 hydroxyalkyl and R2 represents C6-C10 aryl, C1-C4 alkyl or C1-C4 hydroxyalkyl; and R3 represents a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10-membered heteroaryl or 5- to 10-membered heterocyclyl moiety, said aryl, carbocyclyl, heteroaryl and heterocyclyl groups being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxy, thiol, —NH2, C1-C4 hydroxyalkyl, C1-C4 thioalkyl and C1-C4aminoalkyl substituents.Type: ApplicationFiled: January 30, 2006Publication date: May 15, 2008Applicant: ARROW THERAPEUTICS LIMITEDInventors: George Stuart Cockerill, Stephen Sean Flack, Neil Mathews, James Iain Salter
-
Publication number: 20040006434Abstract: A method for identifying an essential gene of an organism, which method comprises: (i) providing a library of transposon insertion mutants of the said organism, wherein the transposon comprises an RNA polymerase recognition sequence; (ii) isolating chromosomal DNA from the library of (i), (iii) digesting the chromosomal DNA with a restriction endonuclease that is capable of cutting 5′ of the RNA polymerase recognition site in the transposon and 3′ of the RNA polymerase recognition site in the chromosomal DNA flanking the transposon; (iv) self-ligating the digested DNA, (v) amplifying the self-ligated DNA by inverse PCR (iPCR), (vi) transcribing RNA from the amplified DNA, (vii) hybridising the transcribed RNA with an oligonucleotide array; and (viii) identifying a probe on the oligonucleotide array which corresponds to an essential gene of the organism.Type: ApplicationFiled: February 3, 2003Publication date: January 8, 2004Applicant: ARROW THERAPEUTICS LIMITEDInventors: Ian G. Charles, Andrew Allen, Duncan J. Maskell
-
Patent number: 6406878Abstract: A method for identifying an inhibitor of dehydroquinate synthase (DHQS) and/or dehydroquinase (DQ), which method comprises: i) contacting a test substance with DHQS and a substrate for DHQS and contacting the resulting reaction mixture with DQ, or contacting the test substance with DQ and a substrate for DQ; and ii) contacting the resulting reaction mixture with dehydroshikimate dehydratase (DHSD); and iii) determining whether the test substance inhibits the activity of DHQS or DQ.Type: GrantFiled: March 2, 2001Date of Patent: June 18, 2002Assignee: Arrow Therapeutics LimitedInventors: Alastair Robert Hawkins, Heather Kim Lamb, Ian George Charles